Overview

Canakinumab for Pyoderma Gangrenosum

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.
Phase:
Phase 2
Details
Lead Sponsor:
University of Zurich
Treatments:
Antibodies, Monoclonal